
Joanne L Dickinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9393744/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer. Breast Cancer Research and Treatment, 2022, 192, 89-100.	2.5	4
2	Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition. Prostate, 2022, 82, 540-550.	2.3	3
3	Urban–rural prostate cancer disparities in a regional state of Australia. Scientific Reports, 2022, 12, 3022.	3.3	4
4	A rare variant in <scp><i>EZH2</i></scp> is associated with prostate cancer risk. International Journal of Cancer, 2021, 149, 1089-1099.	5.1	9
5	â€ [~] Pollen potency': the relationship between atmospheric pollen counts and allergen exposure. Aerobiologia, 2021, 37, 825-841.	1.7	12
6	Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C. European Journal of Cancer, 2021, 159, 52-55.	2.8	3
7	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e001127.	3.0	13
8	Recurrence patterns identify aggressive form of human papillomavirusâ€dependent vulvar cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 231-237.	1.0	1
9	Epigenetic regulation of the ITGB4 gene in prostate cancer. Experimental Cell Research, 2020, 392, 112055.	2.6	14
10	Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells. Journal of Cellular Physiology, 2018, 233, 3439-3453.	4.1	12
11	NLRP3 inflammasome in colitis and colitis-associated colorectal cancer. Mammalian Genome, 2018, 29, 817-830.	2.2	41
12	Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation. Pathology, 2018, 50, 622-628.	0.6	7
13	Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies. Blood, 2017, 130, 86-88.	1.4	11
14	Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. Scientific Reports, 2017, 7, 17778.	3.3	8
15	Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. Genome Medicine, 2017, 9, 85.	8.2	17
16	Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and In Vivo. Journal of Cellular Physiology, 2016, 231, 688-697.	4.1	37
17	The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1. Journal of Cellular Biochemistry, 2016, 117, 49-58.	2.6	7
18	Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses. Clinical Epigenetics, 2016, 8, 75.	4.1	10

JOANNE L DICKINSON

#	Article	IF	CITATIONS
19	Precision medicine: drowning in a regulatory soup?. Journal of Law and the Biosciences, 2016, 3, 281-303.	1.6	18
20	Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 46028-46041.	1.8	20
21	Regulation of the <i>ITGA2</i> gene by epigenetic mechanisms in prostate cancer. Prostate, 2015, 75, 723-734.	2.3	24
22	A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study. Oncology Reports, 2015, 33, 25-32.	2.6	9
23	Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential. Marine Drugs, 2015, 13, 2327-2346.	4.6	245
24	Genetic Determinants of Epigenetic Patterns: Providing Insight into Disease. Molecular Medicine, 2015, 21, 400-409.	4.4	10
25	Community Engagement for Big Epidemiology: Deliberative Democracy as a Tool. Journal of Personalized Medicine, 2014, 4, 459-474.	2.5	49
26	Runs of homozygosity and a cluster of vulvar cancer in young Australian Aboriginal women. Gynecologic Oncology, 2014, 133, 421-426.	1.4	14
27	Genetic and epigenetic variation in vulvar cancer: Current research and future clinical practice. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 406-411.	1.0	6
28	New avenues within community engagement: addressing the ingenuity gap in our approach to health research and future provision of health care. Journal of Responsible Innovation, 2014, 1, 321-328.	4.9	12
29	The Familial Tasmanian Haematological Malignancies Study (FaTHMS) : Its origins, its history and the phenomenon of anticipation. Transfusion and Apheresis Science, 2013, 49, 113-115.	1.0	3
30	Emerging Putative Biomarkers: The Role of Alpha 2 and 6 Integrins in Susceptibility, Treatment, and Prognosis. Prostate Cancer, 2012, 2012, 1-9.	0.6	15
31	Ethical genetic research in Indigenous communities: challenges and successful approachesâ~†. Trends in Molecular Medicine, 2012, 18, 702-708.	6.7	18
32	Anticipation in familial hematologic malignancies. Blood, 2011, 117, 1308-1310.	1.4	13
33	Epigenetic regulation of prostate cancer. Clinical Epigenetics, 2011, 2, 151-169.	4.1	34
34	APOE Genotype and Cardio-Respiratory Fitness Interact to Determine Adiposity in 8-Year-Old Children from the Tasmanian Infant Health Survey. PLoS ONE, 2011, 6, e26679.	2.5	13
35	Evidence for a common genetic aetiology in highâ€risk families with multiple haematological malignancy subtypes. British Journal of Haematology, 2010, 150, 456-462.	2.5	7
36	Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Multiple Sclerosis Journal, 2009, 15, 563-570.	3.0	82

JOANNE L DICKINSON

#	Article	IF	CITATIONS
37	Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. European Journal of Human Genetics, 2009, 17, 368-377.	2.8	26
38	Sequence variants of αâ€methylacyl oA racemase are associated with prostate cancer risk: A replication study in an ethnically homogeneous population. Prostate, 2008, 68, 1373-1379.	2.3	13
39	CTLA-4 and multiple sclerosis: The A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. Journal of Neuroimmunology, 2008, 196, 139-142.	2.3	8
40	Mutations in the <i>NDP</i> gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clinical and Experimental Ophthalmology, 2006, 34, 682-688.	2.6	76
41	Does the Addition of Information on Genotype Improve Prediction of the Risk of Melanoma and Nonmelanoma Skin Cancer beyond That Obtained from Skin Phenotype?. American Journal of Epidemiology, 2004, 159, 826-833.	3.4	56
42	Genetic Dissection of the Human Leukocyte Antigen Region by Use of Haplotypes of Tasmanians with Multiple Sclerosis. American Journal of Human Genetics, 2002, 70, 1125-1137.	6.2	93
43	The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF- $\hat{1}$ ± induced apoptosis. Cell Death and Differentiation, 1998, 5, 163-171.	11.2	57
44	DNase I hypersensitive sites in the 5' flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-alpha-induced transcription in monocytes. FEBS Journal, 1998, 256, 550-559.	0.2	3
45	The Serine Proteinase Inhibitor (Serpin) Plasminogen Activation Inhibitor Type 2 Protects against Viral Cytopathic Effects by Constitutive Interferon α/β Priming. Journal of Experimental Medicine, 1998, 187, 1799-1811.	8.5	75
46	Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor α-induced Apoptosis. Journal of Biological Chemistry, 1995, 270, 27894-27904.	3.4	195
47	Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell. Teratogenesis, and Mutagenesis, 1993, 13, 75,88	0.8	15